Pharmacogenomic Data “Regulatory Impact” To Be Outlined In Guidance

The regulatory impact of different categories of pharmacogenomic data will be addressed in a draft guidance, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said at FDA's Science Board Advisory Committee meeting April 9